RankAlpha logo
Back to Rankings

RLMD

Relmada TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The bull case is that RLMD now has a reset pipeline with NDV-01 as the lead asset, sepranolone as a second program, and enough cash to reach targeted mid-2026 development milestones; successful IND/trial-start execution could move the stock closer to its sparse published target backdrop [#10-K-2026-03-19].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.0.
What can break
Additional financing or partnering may be needed beyond the stated 12-month funding horizon.
Momentum
90
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $10.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $10.75
Why
Momentum90 · Δ7d -4.0
Value41 · Δ7d +0.1
Sentiment62 · Δ7d +6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
90
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-4.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
62
33% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+15.3
Why this grade

Composite grade A. Momentum 90.4 / Value 41.1 / Sentiment 61.5

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$673.4M
Beta
0.78
Shares Out
73.33M
P/E (TTM) · Derived
-3.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.29
Rev YoY
-
EPS YoY
+57.8%
Gross Margin
-
Op Margin
-
Net Debt
-$44.91M
Current Ratio
2.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology